- Conditions
- Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
- Interventions
- atumelnant (CRN04894)
- Drug
- Lead sponsor
- Crinetics Pharmaceuticals Inc.
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 8
- States / cities
- Pasadena, California • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more
Location Directory
Clinical trials in Minneapolis, Minnesota
This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7879
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 997–1008 of 7,879 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Cardiovascular Risk, Acute Myocardial Infarction (AMI)
- Interventions
- Ziltivekimab, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 188
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 156 more
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- M5049 dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Vonicog Alfa, ADVATE
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Orlando, Florida • Peoria, Illinois + 9 more
- Conditions
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
- Interventions
- BBP-418 (ribitol), Placebo
- Drug · Other
- Lead sponsor
- ML Bio Solutions, Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Irvine, California • Aurora, Colorado + 9 more
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Interventions
- Petrelintide, Placebo
- Drug · Other
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 48
- States / cities
- Cullman, Alabama • Chandler, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Hypochondroplasia
- Interventions
- Vosoritide
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2044
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Oakland, California • Wilmington, Delaware + 7 more
- Conditions
- Post-Acute COVID-19 Syndrome
- Interventions
- Baricitinib 4 MG, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
- Conditions
- Smoking
- Interventions
- Minimally Ventilated non-menthol cigarettes, Ventilated non-menthol cigarettes
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Amputation
- Interventions
- Multiaxial Prosthetic Foot Emulator, Commercially available prosthetic feet
- Device
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Chronic Kidney Disease
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 119
- States / cities
- Huntsville, Alabama • Montgomery, Alabama • Sheffield, Alabama + 106 more
- Conditions
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
- Interventions
- Osimertinib, Osimertinib + Chemotherapy
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more